SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Monsanto Co. -- Ignore unavailable to you. Want to Upgrade?


To: Anthony Wong who wrote (735)12/8/1998 11:25:00 PM
From: Ricky Wang  Read Replies (1) | Respond to of 2539
 
"Merck is expected to discuss tomorrow whether the FDA will
grant a priority review for Vioxx. If it does win accelerated
review, it could be introduced about six months after Monsanto's
Celebrex. If not, it could follow by about a year."

Anthony, I thought that only the first drug in a class could get FDA priority status. After Celebrex, wouldn't that rule out Vioxx?